Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.
The drug of choice for the treatment of iron poisoning is desferrioxamine, though the best route of administration, dose, and duration of treatment are unclear. We report fatal lung injury in four patients who were treated with continuous intravenous infusions. The patients, aged 19-26 years, had received desferrioxamine infusions of 15 mg/kg per h for 65-92 h. Respiratory distress developed after 32-72 h. The patients met clinical, physiological, and necropsy criteria for the diagnosis of adult respiratory distress syndrome (ARDS); none had any of the known risk factors for the development of this disorder. We reviewed the records of forty-three iron-poisoned patients treated with desferrioxamine infusions. No patient treated for less than 24 h had pulmonary complications; however, of the fourteen treated for longer than 24 h, four were the patients with ARDS and four others had pulmonary oedema of other causes. We suggest that the pulmonary complications are caused by continuous infusion of desferrioxamine and that the ARDS in these patient was a consequence of free-radical generation. We recommend that desferrioxamine infusion should not be administered for longer than 24 h.
Departments of Pediatrics, Pharmacology, and Medicine, University of Manitoba, Winnipeg, Canada.
M
M
Tenenbein
S
S
Kowalski
A
A
Sienko
D H
DH
Bowden
I Y
IY
Adamson
D000208:Acute Disease; D000328:Adult; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000506:poisoning*; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D011041:Poisoning / Q000628:therapy; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000473:pathology
D007501:Iron; D003676:Deferoxamine